1OHR

VIRACEPT (R) (NELFINAVIR MESYLATE, AG1343): A POTENT ORALLY BIOAVAILABLE INHIBITOR OF HIV-1 PROTEASE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Kaldor, S.W.Kalish, V.J.Davies 2nd., J.F.Shetty, B.V.Fritz, J.E.Appelt, K.Burgess, J.A.Campanale, K.M.Chirgadze, N.Y.Clawson, D.K.Dressman, B.A.Hatch, S.D.Khalil, D.A.Kosa, M.B.Lubbehusen, P.P.Muesing, M.A.Patick, A.K.Reich, S.H.Su, K.S.Tatlock, J.H.

(1997) J Med Chem 40: 3979-3985

  • DOI: https://doi.org/10.1021/jm9704098
  • Primary Citation of Related Structures:  
    1OHR

  • PubMed Abstract: 

    Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343 (Viracept, nelfinavir mesylate), a nonpeptidic inhibitor of HIV-1 protease, was identified. AG1343 is a potent enzyme inhibitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM). An X-ray cocrystal structure of the enzyme-AG1343 complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively. In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. AG1343 (Viracept) has recently been approved for marketing for the treatment of AIDS.


  • Organizational Affiliation

    Agouron Pharmaceuticals, Inc., San Diego, California 92121, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
ASPARTYLPROTEASE
A, B
99Human immunodeficiency virus 1Mutation(s): 0 
UniProt
Find proteins for Q9Q288 (Human immunodeficiency virus 1)
Explore Q9Q288 
Go to UniProtKB:  Q9Q288
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9Q288
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
1UN
Query on 1UN

Download Ideal Coordinates CCD File 
C [auth A]2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
C32 H45 N3 O4 S
QAGYKUNXZHXKMR-HKWSIXNMSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
1UN BindingDB:  1OHR Ki: min: 0.07, max: 2 (nM) from 2 assay(s)
Kd: min: 3, max: 38 (nM) from 3 assay(s)
IC50: min: 1.9, max: 530 (nM) from 3 assay(s)
PDBBind:  1OHR Ki: 2 (nM) from 1 assay(s)
Binding MOAD:  1OHR Ki: 2 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.10 Å
  • R-Value Work: 0.200 
  • R-Value Observed: 0.200 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 52.04α = 90
b = 59.38β = 90
c = 61.67γ = 90
Software Package:
Software NamePurpose
X-PLORmodel building
X-PLORrefinement
X-PLORphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 1998-12-09
    Type: Initial release
  • Version 1.1: 2008-03-03
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2024-02-14
    Changes: Data collection, Database references, Derived calculations, Other